Clinical trials tracking nonalcoholic fatty liver disease: Drug classification
10.3969/j.issn.1001-5256.2018.12.002
- VernacularTitle:跟踪非酒精性脂肪性肝病的临床试验–药物分类
- Author:
Han JIA
1
;
Huiying RAO
Author Information
1. Peking University Hepatology Institute, People′s Hospital, Peking University, Beijing 100044, China
- Publication Type:Research Article
- Keywords:
non-alcoholic fatty liver disease;
drugs, investigational;
metabolic syndrome X;
liver cirrhosis
- From:
Journal of Clinical Hepatology
2018;34(12):2495-2500
- CountryChina
- Language:Chinese
-
Abstract:
At present, there are still no effective drugs launched for the treatment of nonalcoholic fatty liver disease (NAFLD), and many drugs are being evaluated in clinical trials. These drugs have different mechanisms of action in treatment, such as improvement of glycolipid metabolism, anti-inflammation, anti-fibrosis, and improvement of intestinal microbiota. This article elaborates on the research and development of drugs from the following aspects: inflammatory response and immune activation, lipid metabolism and insulin resistance, lipotoxicity, oxidative stress, cell apoptosis and necrosis, collagen formation and degradation, and proliferation of intestinal microbiota.
